• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

SIRT2-KLF4 相互作用对骨髓瘤的存活和迁移至关重要。

SIRT2-KLF4 Interactions are Critical for Myeloma Survival and Migration.

机构信息

Department of Blood Transfusion, Heilongjiang Provincial Hospital, Harbin, Heilongjiang 150036, China.

Department of Nutrition, Heilongjiang Provincial Hospital, Harbin, Heilongjiang 150036, China.

出版信息

Comput Intell Neurosci. 2022 May 27;2022:7356477. doi: 10.1155/2022/7356477. eCollection 2022.

DOI:10.1155/2022/7356477
PMID:35669651
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9166995/
Abstract

OBJECTIVE

To investigate the roles and possible mechanisms of SIRT2 and KLF4 in the development and progression of myeloma.

METHODS

Rt-PCR was used to detect SIRT2 in myeloma samples from patients and myeloma cells, the expression level of KLF4 in myeloma cells, and the effect of downregulation of SIRT2 expression on KLF4 expression level. MTT assay and wound-healing assay were used to observe the proliferation and migration of U266cells transient transfected with Sirt2 inhibitors.

RESULTS

SIRT2 is highly expressed in myeloma, but KLF4 was down. Downregulation of SIRT2 expression stimulated the expression level of KLF4. Reduced SIRT2 activity results in the release of KLF4 expression, which inhibits the proliferation and migration of myeloma cells.

CONCLUSION

SIRT2-KLF4 combination plays an important role in the occurrence and development of myeloma.

摘要

目的

研究 SIRT2 和 KLF4 在骨髓瘤发生和发展中的作用及其可能的机制。

方法

采用 RT-PCR 检测骨髓瘤患者和骨髓瘤细胞中的 SIRT2，骨髓瘤细胞中 KLF4 的表达水平，以及下调 SIRT2 表达对 KLF4 表达水平的影响。MTT 检测和划痕愈合试验观察 Sirt2 抑制剂瞬时转染 U266 细胞的增殖和迁移。

结果

SIRT2 在骨髓瘤中高表达，但 KLF4 下调。下调 SIRT2 表达可刺激 KLF4 的表达水平。降低 SIRT2 活性可导致 KLF4 表达释放，从而抑制骨髓瘤细胞的增殖和迁移。

结论

SIRT2-KLF4 组合在骨髓瘤的发生和发展中起重要作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed06/9166995/92790c0b4c03/CIN2022-7356477.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed06/9166995/2a58dd1868d6/CIN2022-7356477.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed06/9166995/61b4358cbc75/CIN2022-7356477.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed06/9166995/d598f08e5da5/CIN2022-7356477.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed06/9166995/1d31c53b3311/CIN2022-7356477.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed06/9166995/d05691cdc676/CIN2022-7356477.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed06/9166995/92790c0b4c03/CIN2022-7356477.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed06/9166995/2a58dd1868d6/CIN2022-7356477.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed06/9166995/61b4358cbc75/CIN2022-7356477.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed06/9166995/d598f08e5da5/CIN2022-7356477.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed06/9166995/1d31c53b3311/CIN2022-7356477.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed06/9166995/d05691cdc676/CIN2022-7356477.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed06/9166995/92790c0b4c03/CIN2022-7356477.006.jpg

相似文献

1
SIRT2-KLF4 Interactions are Critical for Myeloma Survival and Migration.SIRT2-KLF4 相互作用对骨髓瘤的存活和迁移至关重要。
Comput Intell Neurosci. 2022 May 27;2022:7356477. doi: 10.1155/2022/7356477. eCollection 2022.
2
Sirtuin 2 knockdown inhibits cell proliferation and RAS/ERK signaling, and promotes cell apoptosis and cell cycle arrest in multiple myeloma.沉默 Sirtuin 2 可抑制骨髓瘤细胞增殖和 RAS/ERK 信号通路，促进细胞凋亡和细胞周期阻滞。
Mol Med Rep. 2021 Nov;24(5). doi: 10.3892/mmr.2021.12400. Epub 2021 Sep 3.
3
SIRT2 and SIRT3 expression correlates with redox imbalance and advanced clinical stage in patients with multiple myeloma.SIRT2 和 SIRT3 的表达与多发性骨髓瘤患者的氧化还原失衡和晚期临床阶段相关。
Clin Biochem. 2021 Jul;93:42-49. doi: 10.1016/j.clinbiochem.2021.04.002. Epub 2021 Apr 20.
4
Reduced expression of SIRT2 in serous ovarian carcinoma promotes cell proliferation through disinhibition of CDK4 expression.浆液性卵巢癌中SIRT2表达降低通过解除对CDK4表达的抑制作用促进细胞增殖。
Mol Med Rep. 2017 Apr;15(4):1638-1646. doi: 10.3892/mmr.2017.6183. Epub 2017 Feb 8.
5
Sirtuin 2 in Endometrial Cancer: A Potential Regulator for Cell Proliferation, Apoptosis and RAS/ERK Pathway.Sirtuin 2 在子宫内膜癌中的作用：细胞增殖、凋亡和 RAS/ERK 通路的潜在调节剂。
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820980781. doi: 10.1177/1533033820980781.
6
[Expression Level of SIRT2 in Cervical Cancer Tissue and Its Clinical Significance].[宫颈癌组织中SIRT2的表达水平及其临床意义]
Sichuan Da Xue Xue Bao Yi Xue Ban. 2019 Sep;50(5):701-707.
7
SIRT2 Affects Cell Proliferation and Apoptosis by Suppressing the Level of Autophagy in Renal Podocytes.SIRT2 通过抑制肾足细胞自噬水平影响细胞增殖和凋亡。
Dis Markers. 2022 Apr 22;2022:4586198. doi: 10.1155/2022/4586198. eCollection 2022.
8
SIRT2 Contributes to the Regulation of Intestinal Cell Proliferation and Differentiation.SIRT2 有助于调节肠道细胞增殖和分化。
Cell Mol Gastroenterol Hepatol. 2020;10(1):43-57. doi: 10.1016/j.jcmgh.2020.01.004. Epub 2020 Jan 16.
9
E3 Ubiquitin Ligase HRD1 Promotes Lung Tumorigenesis by Promoting Sirtuin 2 Ubiquitination and Degradation.E3 泛素连接酶 HRD1 通过促进 Sirtuin 2 的泛素化和降解促进肺肿瘤发生。
Mol Cell Biol. 2020 Mar 16;40(7). doi: 10.1128/MCB.00257-19.
10
Expression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients.沉默调节蛋白1和2的表达与非小细胞肺癌患者的不良预后相关。
PLoS One. 2015 Apr 27;10(4):e0124670. doi: 10.1371/journal.pone.0124670. eCollection 2015.

引用本文的文献

1
Retracted: SIRT2-KLF4 Interactions are Critical for Myeloma Survival and Migration.撤回：SIRT2与KLF4的相互作用对骨髓瘤的存活和迁移至关重要。
Comput Intell Neurosci. 2023 Jan 9;2023:9821928. doi: 10.1155/2023/9821928. eCollection 2023.

本文引用的文献

1
Sirtuin 2 knockdown inhibits cell proliferation and RAS/ERK signaling, and promotes cell apoptosis and cell cycle arrest in multiple myeloma.沉默 Sirtuin 2 可抑制骨髓瘤细胞增殖和 RAS/ERK 信号通路，促进细胞凋亡和细胞周期阻滞。
Mol Med Rep. 2021 Nov;24(5). doi: 10.3892/mmr.2021.12400. Epub 2021 Sep 3.
2
3,3'-Diindolylmethane Enhances Paclitaxel Sensitivity by Suppressing DNMT1-Mediated KLF4 Methylation in Breast Cancer.3,3'-二吲哚甲烷通过抑制DNMT1介导的乳腺癌中KLF4甲基化增强紫杉醇敏感性
Front Oncol. 2021 Jun 3;11:627856. doi: 10.3389/fonc.2021.627856. eCollection 2021.
3
SIRT2 and SIRT3 expression correlates with redox imbalance and advanced clinical stage in patients with multiple myeloma.
SIRT2 和 SIRT3 的表达与多发性骨髓瘤患者的氧化还原失衡和晚期临床阶段相关。
Clin Biochem. 2021 Jul;93:42-49. doi: 10.1016/j.clinbiochem.2021.04.002. Epub 2021 Apr 20.
4
Sirtuin2 correlates with lymph node metastasis, increased FIGO stage, worse overall survival, and reduced chemosensitivity to cisplatin and paclitaxel in endometrial cancer.Sirtuin2 与淋巴结转移、FIGO 分期升高、总生存期缩短以及对顺铂和紫杉醇化疗敏感性降低相关，在子宫内膜癌中。
Ir J Med Sci. 2022 Feb;191(1):147-154. doi: 10.1007/s11845-021-02516-3. Epub 2021 Feb 10.
5
Multiple myeloma.多发性骨髓瘤。
Lancet. 2021 Jan 30;397(10272):410-427. doi: 10.1016/S0140-6736(21)00135-5.
6
MicroRNA-7 Regulates Migration and Chemoresistance in Non-Hodgkin Lymphoma Cells Through Regulation of KLF4 and YY1.微小RNA-7通过调控KLF4和YY1来调节非霍奇金淋巴瘤细胞的迁移和化疗耐药性。
Front Oncol. 2020 Oct 27;10:588893. doi: 10.3389/fonc.2020.588893. eCollection 2020.
7
The Clinical Significance of SIRT2 in Malignancies: A Tumor Suppressor or an Oncogene?SIRT2在恶性肿瘤中的临床意义：肿瘤抑制因子还是癌基因？
Front Oncol. 2020 Sep 8;10:1721. doi: 10.3389/fonc.2020.01721. eCollection 2020.
8
KLF4 in Macrophages Attenuates TNF-Mediated Kidney Injury and Fibrosis.KLF4 在巨噬细胞中减轻 TNF 介导的肾损伤和纤维化。
J Am Soc Nephrol. 2019 Oct;30(10):1925-1938. doi: 10.1681/ASN.2019020111. Epub 2019 Jul 23.
9
Toward personalized treatment in multiple myeloma based on molecular characteristics.基于分子特征的多发性骨髓瘤个体化治疗。
Blood. 2019 Feb 14;133(7):660-675. doi: 10.1182/blood-2018-09-825331. Epub 2018 Dec 26.
10
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma.一项针对复发或难治性多发性骨髓瘤患者的靶向 B 细胞成熟抗原嵌合抗原受体 T 细胞疗法 LCAR-B38M 的 1 期、开放性研究。
J Hematol Oncol. 2018 Dec 20;11(1):141. doi: 10.1186/s13045-018-0681-6.